Stay away from concomitant utilization of tucatinib with CYP3A substrates, where negligible concentration changes may possibly produce major or lifetime-threatening toxicities. If unavoidable, lower CYP3A substrate dose In line with merchandise labeling.Drug interaction with fluoxetine A numerous-dose study was conducted to evaluate the result of f